Stifel analyst Alex Thompson raised the firm’s price target on AnaptysBio (ANAB) to $85 from $56 and keeps a Buy rating on the shares. Following AnaptysBio’s Q4 update, the firm notes that operations are underway for the spin-off of the biopharma portfolio into First Tracks Biotherapeutics (TRAX) in Q2 and that the company expects to give an update on rosnilimab Phase 3 RA development plans in Q2 as well.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Risks Loom for AnaptysBio’s Proposed Breakup: Market Value, Volatility and Execution Challenges Highlighted
- AnaptysBio: Structural Separation and Advancing Autoimmune Pipeline Support Overweight Rating and Value Upside
- AnaptysBio price target raised to $66 from $51 at H.C. Wainwright
- AnaptysBio price target raised to $79 from $78 at Barclays
- AnaptysBio provides update on potential spin-off of biopharma operations